Founded in 2001, AM-Pharma is a private company that is based in Bunnik, the Netherlands. The Company is backed by a strong syndicate of international investors, both Venture Capital funds and Corporate Venture Funds, and has raised over €65 million equity to date.
In 2015, Pfizer acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury (AKI) related to sepsis.
AM-Pharma has discovered that a key function of Alkaline Phosphatase (AP) is to protect organs against inflammation and tissue damage. While AP is found in many extracellular tissues of the human body, it is present at reduced levels in certain conditions including Acute Kidney Injury (AKI), Ulcerative Colitis (UC) and Hypophosphatasia (HPP). The Company’s proprietary therapeutics are disease modifying therapies with the potential to be “first-in-class” medicines.
Clinical proof-of-concept in two indications was confirmed by the positive results from Phase II clinical studies using native bovine AP, which demonstrated efficacy in patients with AKI and in patients with Moderate-to-Severe UC (a form of Inflammatory Bowel Disease).
AM-Pharma is now fully focusing on the development of the proprietary recombinant human form of this enzyme (recAP) for treatment of patients with AKI, UC or HPP. The company’s lead product, an intravenous formulation of recAP, is currently being investigated in a large Phase II clinical study in patients with sepsis-associated AKI.